November 22, 2011

As described in the report, which is published analytical company «Deloitte», recently pharmaceutical companies   began to receive less revenue due to the fact that the price of the new output drug   the market has increased by about a quarter, which in absolute terms amounted to more than $ 1 billion. The number of drugs that are under development, in turn, decreased. Also, almost all the companies reported a decline in the profitability of the new developments. Data were collected on the basis of a study of 12 pharmaceutical companies. Thus, experts fear that if the situation will continue to evolve at the same pace, we could lose all the leading developers of new drugs.

Despite the negative side, some manufacturers still celebrate a surplus, even with the current situation - says the head of one of the divisions of «Deloitte» Julian Remnant. It is also pleased that the recent trend to reduce costs, however, except for the sphere of innovations. As a result, the company will still get their profit.

But some companies have decided on a different approach to the issue of new drugs. Pfizer Inc., for example, to opt out of further development of its own in favor of the purchase of patents and rights to obtain new funds from specialized scientific issledovatelkih institutions and biotech laboratories. Thus, for the previous year for the first time producing firms managed to reduce their costs.

J. Remnant commented on this situation in a way that is really a good opportunity to improve the situation on the market is more closely research institutions and pharmaceutical companies, as well as other actors of the market.